M&A Deal Summary

Rhythm Pharmaceuticals Acquires Xinvento

On February 27, 2023, Rhythm Pharmaceuticals acquired life science company Xinvento

Acquisition Highlights
  • This is Rhythm Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Rhythm Pharmaceuticals’ 1st transaction in the Netherlands.

M&A Deal Summary
Date 2023-02-27
Target Xinvento
Sector Life Science
Buyer(s) Rhythm Pharmaceuticals
Deal Type Add-on Acquisition

Target

Xinvento

Amsterdam, Netherlands
website
Xinvento is a biotech company focused on developing therapies for congenital hyperinsulinism (CHI). Xinvento was founded in 2021 and is based in Amsterdam, Netherlands.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Rhythm Pharmaceuticals

Boston, Massachusetts, United States

website

Category Company
Founded 2008
Sector Medical Products
DESCRIPTION

Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in gastrointestinal diseases and obesity, including obesity caused by genetic deficiencies in the MC4 pathway.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
Country (Netherlands) 1 of 1
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-27 Motus Therapeutics

Boston, United States

Motus Therapeutics, Inc. is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases.

Buy -
Mergr

Product

Company

Legal